Eli Lilly presented detailed phase 3 data for retatrutide, a triple-G obesity drug, showing 34.9% of patients on the highest dose lost at least 25% of body weight compared to 4% on placebo. The company plans to file for FDA approval in Q1 2025, positioning retatrutide to compete with its existing tirzepatide while demonstrating superior weight loss but more modest blood sugar effects.